Hemophilia B is a recessive bleeding disorder that results from mutations in the coagulation factor IX
gene on the X chromosome [3-5].
An oral presentation will focus on the pivotal trial for CSL Behring's novel, long-acting albumin fusion protein linking recombinant coagulation factor IX
with recombinant albumin (rIX-FP) for the treatment of hemophilia B.
2, ATC code: B02BD01, Generic Name: Coagulation Factor IX
, II, VII and X in combination Pharmaceutical form: Infusion Strength: 1000 IU, Unit 350 U, Quantity in units: 10thThe above drugs provided under contract number each independently of the other drugs.
It is a coagulation factor IX
(recombinant) indicated in adults and children[greater than or equal to] 12 years of age with hemophilia B for control and prevention of bleeding episodes, and for perioperative management.
Under the terms of the agreement with WFH, at least 85 percent of donated factor will be Antihemophilic Factor VIII (Recombinant), Fc Fusion Protein for the treatment of haemophilia A, with the remainder comprised of Coagulation Factor IX
(Recombinant), Fc Fusion Protein for the treatment of haemophilia B.
Contract notice: Concentrate recombinant coagulation factor ix
least second generation, the investigation sign: zzp-156/15.
MELBOURNE, Australia, May 12, 2014 /PRNewswire/ -- Interim Phase II/III and III findings presented today by CSL Behring at the World Federation of Hemophilia (WFH) 2014 Congress demonstrate an improved pharmacokinetic (PK) profile of recombinant fusion protein linking coagulation factor IX
with recombinant albumin (rIX-FP) among hemophilia B patients of all age groups.
Developed by CSL Behring, rIX-FP is a recombinant fusion protein linking coagulation factor IX
BERN, Switzerland, July 28, 2015 /PRNewswire/ -- CSL Behring announced today that Swissmedic has accepted for review a Marketing Authorization Application (MAA) for the company's investigational long-acting fusion protein linking recombinant coagulation factor IX
with recombinant albumin (rIX-FP) for the prophylaxis and treatment of bleeding episodes in people with Hemophilia B.
This report includes treatments for hemophilia A, B, and C, namely, recombinant factor VIII and coagulation factor IX
, and Desmopressin (DDAVP) which stimulates the release of factor VIII and also increases the level of proteins in the blood.
Wyeth Pharmaceuticals, a division of Wyeth (NYSE: WYE), announced today that it has assumed all marketing and distribution rights to BeneFIX(R) Coagulation Factor IX
(Recombinant) in Europe.
The AFFINITY clinical development program is studying CSL Behring's recombinant Factor VIII SingleChain (rVIII-SingleChain) to treat hemophilia A and the PROLONG-9FP clinical trial program is studying the company's recombinant fusion protein linking coagulation factor IX
with recombinant albumin (rIX-FP) to treat hemophilia B.